H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Renalytix to $8 from $10 and keeps a Buy rating on the shares after the company reported results for fiscal Q1 earlier this week. Of note, the company performed over 1,200 KidneyIntelX tests during the quarter and Chen believes newly published real-world evidence could drive further adoption of KidneyIntelX at several participating health systems as well as VHA centers, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RNLX:
- Renalytix announces highlights from publication of data on use of KidneyIntelX
- Renalytix reports Q1 EPS (16c), consensus (13c)
- Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023
- Renalytix announces publication highlighting KidneyIntelX test
- Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease